KR20160125988A - 리신 22의 엡실론 위치에서의 a22k, desb27, b29r, des b30 아실화 사람 인슐린 유사체 - Google Patents

리신 22의 엡실론 위치에서의 a22k, desb27, b29r, des b30 아실화 사람 인슐린 유사체 Download PDF

Info

Publication number
KR20160125988A
KR20160125988A KR1020167024826A KR20167024826A KR20160125988A KR 20160125988 A KR20160125988 A KR 20160125988A KR 1020167024826 A KR1020167024826 A KR 1020167024826A KR 20167024826 A KR20167024826 A KR 20167024826A KR 20160125988 A KR20160125988 A KR 20160125988A
Authority
KR
South Korea
Prior art keywords
insulin
desb27
human insulin
eps
gglu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167024826A
Other languages
English (en)
Korean (ko)
Inventor
피터 마드센
수잔느 호스트럽
마르틴 문젤
토마스 뵈글룸 켈드센
클라우디아 울리크 회링가아드
크리스티안 플레델리우스
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Publication of KR20160125988A publication Critical patent/KR20160125988A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
KR1020167024826A 2014-02-28 2015-02-26 리신 22의 엡실론 위치에서의 a22k, desb27, b29r, des b30 아실화 사람 인슐린 유사체 Withdrawn KR20160125988A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14157215 2014-02-28
EP14157215.6 2014-02-28
PCT/EP2015/053989 WO2015128403A2 (en) 2014-02-28 2015-02-26 Novel insulin derivatives and the medical uses hereof

Publications (1)

Publication Number Publication Date
KR20160125988A true KR20160125988A (ko) 2016-11-01

Family

ID=50184804

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167024826A Withdrawn KR20160125988A (ko) 2014-02-28 2015-02-26 리신 22의 엡실론 위치에서의 a22k, desb27, b29r, des b30 아실화 사람 인슐린 유사체

Country Status (23)

Country Link
US (1) US10040839B2 (enExample)
EP (1) EP3110840B1 (enExample)
JP (1) JP6580583B2 (enExample)
KR (1) KR20160125988A (enExample)
CN (1) CN106459171B (enExample)
AR (1) AR099569A1 (enExample)
AU (1) AU2015222135B2 (enExample)
BR (1) BR112016017193A2 (enExample)
CA (1) CA2941103A1 (enExample)
DK (1) DK3110840T3 (enExample)
ES (1) ES2831848T3 (enExample)
HR (1) HRP20201732T1 (enExample)
HU (1) HUE051355T2 (enExample)
IL (1) IL246757B (enExample)
MX (1) MX368387B (enExample)
PL (1) PL3110840T3 (enExample)
PT (1) PT3110840T (enExample)
RS (1) RS61137B1 (enExample)
RU (1) RU2684456C2 (enExample)
SA (1) SA516371705B1 (enExample)
SI (1) SI3110840T1 (enExample)
TW (1) TWI686403B (enExample)
WO (1) WO2015128403A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018147624A1 (ko) * 2017-02-09 2018-08-16 강원대학교산학협력단 인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170028031A1 (en) * 2014-03-07 2017-02-02 Klavs Holger Jørgensen Novel fast acting insulin preparations
MX2018002223A (es) 2015-08-25 2018-03-23 Novo Nordisk As Derivados de insulina novedosos y usos medicos de los mismos.
AR110193A1 (es) * 2016-11-21 2019-03-06 Univ Case Western Reserve Análogos de insulina de acción rápida de estabilidad mejorada
CN110505885A (zh) * 2017-04-05 2019-11-26 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
RU2020108281A (ru) * 2017-08-17 2021-08-26 Ново Нордиск А/С Новые ацилированные аналоги инсулина и варианты их применения
US20190290736A1 (en) * 2017-10-19 2019-09-26 Fourward Technology, LLC Topical composition for improved healing of open wounds
TWI829687B (zh) * 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020120463A1 (en) 2018-12-11 2020-06-18 Sanofi Insulin conjugates
CA3127312A1 (en) 2019-02-13 2020-08-20 Sumitomo Dainippon Pharma Co., Ltd. Hemiasterlin derivative having cysteine residue
JP7479302B2 (ja) * 2019-02-13 2024-05-08 住友ファーマ株式会社 ヘミアスタリン誘導体とその抗体薬物複合体
US20220306695A1 (en) * 2019-08-27 2022-09-29 Zp Spv 3 K/S Compstatin analogues and their medical uses
WO2021116292A1 (en) 2019-12-11 2021-06-17 Novo Nordisk A/S Novel insulin analogues and uses thereof
CN118420743A (zh) * 2019-12-30 2024-08-02 甘李药业股份有限公司 胰岛素衍生物
US20240374692A1 (en) * 2021-05-24 2024-11-14 Sunshine Lake Pharma Co., Ltd. A novel acylated insulin analog

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381274A (en) 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3864325A (en) 1971-11-18 1975-02-04 Nat Res Dev (N{HU Al{b , N{HU Bl{b , N{HU B29{B , carbamoyl)-(O{HU A14{B , O{HU B16{B , O{HU B26{B aryl) insulin derivatives
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
FI913037A7 (fi) * 1988-12-23 1991-06-20 Novo Nordisk As Ihmisen insuliinianalogit
DE69019534T2 (de) * 1989-12-21 1995-09-21 Novonordisk As Insulinzubereitungen, die nikotinsäure oder nikotinamid enthalten.
SK282495B6 (sk) 1993-09-17 2002-02-05 Novo Nordisk A/S Acylovaný inzulínový derivát a farmaceutický prostriedok, ktorý ho obsahuje
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6703017B1 (en) * 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US5461031A (en) 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
CA2215694A1 (en) 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5905140A (en) 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
RU2198181C2 (ru) 1997-03-20 2003-02-10 Ново Нордиск А/С Не содержащие цинк кристаллы инсулина для применения в легочных композициях
US6268335B1 (en) 1997-10-24 2001-07-31 Eli Lilly And Company Insoluble insulin compositions
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
PT1025125E (pt) 1997-10-24 2003-11-28 Novo Nordisk As Derivativos agregados da insulina humana
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
ATE290877T1 (de) 1998-01-09 2005-04-15 Novo Nordisk As Stabilisierte insulin-zubereitungen
AU8029798A (en) 1998-06-12 2000-01-05 Deutsches Wollforschungsinstitut Insulin analogue
EP1196446A1 (en) 1999-06-29 2002-04-17 Eli Lilly And Company Protamine-free insoluble acylated insulin compositions
AU2001264789A1 (en) 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
WO2003048195A2 (en) 2001-12-02 2003-06-12 Novo Nordisk A/S Glucose dependant release of insulin from glucose sensing insulin derivatives
PL374949A1 (en) 2001-12-20 2005-11-14 Eli Lilly And Company Insulin molecule having protracted time action
WO2003075950A1 (en) 2002-03-13 2003-09-18 Novo Nordisk A/S Minimising body weight gain in insulin treatment
US20040138099A1 (en) 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
KR20050121748A (ko) 2003-04-29 2005-12-27 일라이 릴리 앤드 캄파니 연장된 시간 작용을 갖는 인슐린 유사체
EP1644411A2 (en) 2003-07-11 2006-04-12 Novo Nordisk A/S Stabilised insulin compositions
US20060183667A1 (en) 2003-07-11 2006-08-17 Novo Nordisk A/S Stabilised insulin compositions
JP4463814B2 (ja) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
CA2535013C (en) 2003-08-13 2013-02-12 Nobex Corporation Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
EP1687428A1 (en) 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
EP1692168B1 (en) 2003-12-03 2011-07-20 Novo Nordisk A/S Single-chain insulin
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
KR101276754B1 (ko) 2004-07-19 2013-06-19 바이오콘 리미티드 인슐린―올리고머 접합체，제형 및 이들의 용도
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
JP4933455B2 (ja) 2005-02-02 2012-05-16 ノヴォ ノルディスク アー／エス 新規のインスリン誘導体
EP1863840A1 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
DK1969004T3 (da) 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
WO2007128815A1 (en) 2006-05-09 2007-11-15 Novo Nordisk A/S Insulin derivative
JP5269767B2 (ja) 2006-05-09 2013-08-21 ノボ・ノルデイスク・エー／エス インスリン誘導体
JP2009544716A (ja) 2006-07-27 2009-12-17 ノバルティス アクチエンゲゼルシャフト 肺送達のためのインスリン含有エアロゾル化可能製剤
ES2542146T3 (es) 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
PL2074141T3 (pl) * 2006-09-22 2017-02-28 Novo Nordisk A/S Analogi insuliny oporne na proteazę
WO2008145721A2 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
EP2167032B1 (en) 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
WO2009015456A1 (en) 2007-07-30 2009-02-05 Generex Pharmaceuticals Inc. Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
WO2009022005A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulin analogues with an acyl and alkylene glycol moiety
WO2009060071A1 (en) 2007-11-08 2009-05-14 Novo Nordisk A/S Insulin derivative
EP2209800B1 (en) 2007-11-16 2013-07-24 Novo Nordisk A/S Stable pharmaceutical compositions comprising liraglutide and degludec
EP2217265B1 (en) 2007-11-20 2017-05-10 Ambrx, Inc. Modified insulin polypeptides and their uses
CN101970477B (zh) * 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
KR20110004366A (ko) 2008-03-18 2011-01-13 노보 노르디스크 에이/에스 프로테아제 안정화되고, 아실화된 인슐린 유사체
JP5591243B2 (ja) 2008-09-12 2014-09-17 ノボ・ノルデイスク・エー／エス ペプチド又はタンパク質のアシル化の方法
WO2010049488A1 (en) 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US8697632B2 (en) 2008-12-19 2014-04-15 Indiana University Research And Technology Corporation Amide based insulin prodrugs
US20120184487A1 (en) 2009-06-30 2012-07-19 Novo Nordisk A/S Insulin derivatives
RU2556340C2 (ru) * 2009-07-31 2015-07-10 Санофи-Авентис Дойчланд Гмбх Композиция инсулина длительного действия
ES2612468T3 (es) 2010-05-10 2017-05-17 Novo Nordisk A/S Procedimiento para la preparación de complejos de insulina-zinc
WO2011161124A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
JP5931857B2 (ja) * 2010-06-23 2016-06-08 ノヴォ ノルディスク アー／エス 追加のジスルフィド結合を含有するインスリン誘導体
WO2012010553A1 (en) 2010-07-20 2012-01-26 Novo Nordisk A/S N-terminal modified fgf21 compounds
EP2720711A1 (en) * 2011-06-15 2014-04-23 Novo Nordisk A/S Multi substituted insulins
CN104010652A (zh) 2011-10-27 2014-08-27 卡斯西部储备大学 超浓缩的速效胰岛素类似物制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018147624A1 (ko) * 2017-02-09 2018-08-16 강원대학교산학협력단 인슐린의 a 사슬로부터 유래된 펩타이드 단편 및 이를 포함하는 당뇨병 또는 당뇨병성 창상의 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
US20170008945A1 (en) 2017-01-12
PT3110840T (pt) 2020-11-26
CA2941103A1 (en) 2015-09-03
HRP20201732T1 (hr) 2020-12-25
MX368387B (es) 2019-10-01
ES2831848T3 (es) 2021-06-09
IL246757B (en) 2020-04-30
WO2015128403A3 (en) 2015-12-10
AR099569A1 (es) 2016-08-03
US10040839B2 (en) 2018-08-07
DK3110840T3 (da) 2020-11-02
WO2015128403A2 (en) 2015-09-03
SA516371705B1 (ar) 2019-10-08
TW201620930A (zh) 2016-06-16
BR112016017193A2 (pt) 2017-10-03
RU2684456C2 (ru) 2019-04-09
JP2017508741A (ja) 2017-03-30
RU2016135543A (ru) 2018-03-30
EP3110840B1 (en) 2020-10-21
AU2015222135B2 (en) 2018-12-20
IL246757A0 (en) 2016-08-31
CN106459171A (zh) 2017-02-22
CN106459171B (zh) 2020-12-15
JP6580583B2 (ja) 2019-09-25
TWI686403B (zh) 2020-03-01
AU2015222135A1 (en) 2016-07-28
PL3110840T3 (pl) 2021-04-06
HUE051355T2 (hu) 2021-03-01
EP3110840A2 (en) 2017-01-04
RU2016135543A3 (enExample) 2018-08-30
MX2016010899A (es) 2016-11-18
SI3110840T1 (sl) 2020-12-31
RS61137B1 (sr) 2020-12-31

Similar Documents

Publication Publication Date Title
KR20160125988A (ko) 리신 22의 엡실론 위치에서의 a22k, desb27, b29r, des b30 아실화 사람 인슐린 유사체
US11352406B2 (en) Insulin derivatives and the medical uses hereof
US20200283493A1 (en) Novel Insulin Derivatives and the Medical Uses Hereof
KR102427426B1 (ko) 신규한 인슐린 유사체 및 이의 용도
US20180244743A1 (en) Novel Insulin Derivatives and the Medical Uses Hereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160907

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200211

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20210205

WITB Written withdrawal of application